Bukwang Pharmaceutical Co., Ltd. · KRX:003000

Bukwang Pharmaceutical Co., Ltd. financial statements

Bukwang Pharmaceutical Co., Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue200.7B160.1B125.9B190.9B182.5B169.7B168.2B194.2B150.7B138.6B
Cost of revenue108.8B85.7B78.9B111.5B106.7B98.0B83.9B79.2B70.1B62.3B
Gross profit91.9B74.3B47.1B79.4B75.8B71.6B84.2B115.0B80.6B76.3B
Research and development19.4B23.4B34.6B24.3B22.5B18.0B17.3B24.6B25.1B18.7B
Selling, general and administrative24.8B16.8B22.1B19.8B13.5B15.3B22.2B20.1B16.5B18.7B
Operating income14.2B1.62B-37.5B-230.6M5.62B4.03B9.54B35.1B7.68B8.54B
Depreciation and amortization5.49B4.11B4.29B5.12B4.84B6.16B5.84B6.88B6.10B5.70B
EBITDA19.7B5.72B-33.2B4.89B10.5B10.2B15.4B42.0B13.8B14.2B
Interest expense3.90B6.49B3.81B1.76B1.41B1.51B90.9M000
Income before tax6.39B-2.97B-39.6B-1.03B3.79B-8.30B-1.36B191.1B14.9B21.0B
Income tax6.58B1.81B6.07B45.4B3.79B5.22B
Net income12.6B-2.64B-31.3B-2.47B-916.6M-7.20B-7.41B145.7B11.1B15.8B
Earnings per share, basic127.28-35.43-457.67-33.19-13.39-115.71-110.562,580.74171.54

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents96.2B90.1B151.2B85.5B82.8B79.3B37.6B100.4B24.2B41.1B
Short-term investments120.0B40.0B1.50B10.3B
Receivables27.8B23.6B35.7B88.0B90.4B103.7B103.0B86.6B60.2B50.3B
Inventory52.2B41.7B56.8B38.6B39.3B51.4B44.1B34.2B39.6B39.4B
Current assets303.2B203.7B254.2B218.7B220.1B248.2B186.4B221.6B124.3B134.0B
Property, plant and equipment124.5B106.3B128.8B128.5B60.2B60.9B
Goodwill0406.6M878.7M834.5M828.7M827.0M796.8M786.5M788.9M782.7M
Total assets476.3B373.2B429.0B400.9B397.4B401.0B388.5B493.6B236.2B237.6B
Accounts payable7.30B5.06B2.37B16.5B7.42B10.2B9.89B4.34B4.68B3.28B
Current liabilities117.8B35.4B97.5B44.6B37.0B61.2B35.9B38.2B19.2B16.8B
Long-term debt79.0B78.5B
Total liabilities135.4B129.0B194.8B129.1B117.4B129.8B62.0B80.2B24.9B23.0B
Shareholders' equity340.6B243.7B226.3B263.2B269.6B258.5B326.2B413.4B211.3B214.6B
Shares outstanding98.7M74.6M68.5M74.6M68.5M62.3M67.0M56.4M64.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations21.5B34.4B-9.36B16.5B26.5B723.2M-23.4B6.82B8.56B-7.76B
Capital spending-11.2B-2.61B-2.83B-4.99B-785.1M-1.92B-3.54B-3.71B-4.49B-5.93B
Free cash flow10.3B31.7B-12.2B11.5B25.7B-1.23B-28.3B3.09B2.03B-13.7B
Cash from investing4.75B13.0B18.1B35.0B-7.45B3.59B
Cash from financing-27.5B28.2B-57.5B34.5B-18.0B-22.3B
Dividends paid-4.93B-6.85B-6.23B-12.2B-9.77B-8.61B-17.9B-22.8B
Share buybacks-2.75B-516.2M-25.1B-50.2B-110.0M-80.3M-87.1M
Change in cash6.12B-61.1B65.7B2.74B3.49B41.7B-62.8B76.2B-16.9B-26.4B